Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07266233

Toluidine Blue-Based Photodynamic Therapy for Antibacterial Activity and Postoperative Pain

This clinical study aims to evaluate the antimicrobial effectiveness and postoperative pain outcomes of photodynamic therapy using Toluidine Blue O as an adjunct to conventional root canal treatment in patients diagnosed with symptomatic irreversible pulpitis. Photodynamic therapy is a non-invasive light-activated disinfection method, and this study will compare its performance with standard endodontic treatment protocols. The results are expected to provide clinical evidence regarding its potential benefits in reducing intracanal bacterial load and improving postoperative patient comfort.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Atatürk University, Faculty of Dentistry, Department of Endodontics

Erzurum, Turkey (Türkiye)

About this study

This randomized clinical study is designed to investigate the antimicrobial effectiveness and postoperative pain outcomes of photodynamic therapy (PDT) using toluidine blue O (TBO) as an adjunct to conventional root canal treatment in single-rooted teeth with necrotic pulps. The rationale for this research is based on the persistent difficulty of achieving complete microbial elimination from the root canal system using standard chemomechanical preparation alone. Toluidine blue O-mediated PDT has been proposed as a minimally invasive disinfection method capable of producing reactive oxygen species after activation with visible light, thereby enhancing microbial reduction beyond that achieved by irrigation protocols.

The study employs a standardized protocol in which intracanal microbiological sampling is conducted at four predefined stages to monitor changes in microbial load throughout treatment. All samples are stored and analyzed using real-time quantitative polymerase chain reaction (qPCR), which allows sensitive detection and quantification of bacterial DNA. This molecular approach offers advantages over culture-based methods by identifying uncultivable or low-abundance bacterial species, providing a more comprehensive evaluation of the antimicrobial effect of PDT.

In the experimental group, photodynamic therapy is performed by introducing a 0.1 mg/mL toluidine blue O solution into the prepared root canal, followed by activation with a 630-nm LED light source. The choice of this wavelength corresponds to the absorption peak of TBO and optimizes energy transfer for singlet oxygen production. A sham procedure is used in the control group to maintain participant masking and ensure methodological consistency. Both groups receive identical chemomechanical preparation and irrigation procedures prior to the assigned intervention.

Pain assessment during the postoperative period is performed using a validated visual analog scale (VAS), providing continuous measurement of patient-reported discomfort during the first week after treatment. The integration of molecular microbiology with clinical pain evaluation allows a combined assessment of both biological and patient-centered outcomes. This study is expected to contribute new in-vivo evidence on the potential benefits of toluidine blue O-based PDT as an adjunctive disinfection method in endodontic therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged between 18 and 65 years
  • Presence of asymptomatic apical periodontitis with necrotic pulp in single-rooted maxillary or mandibular incisors, canines, or premolars
  • Periapical Index (PAI) score ≥ 2
  • Patients classified as ASA I (American Society of Anesthesiologists Physical Status Classification)
  • Preoperative pain score < 50 on the Visual Analog Scale (VAS)

Exclusion criteria

  • Multi-rooted teeth
  • Patients classified as ASA II or higher
  • Pregnant women or those with suspected pregnancy
  • Root canal curvature greater than 25° according to the Schilder method
  • Patients diagnosed with generalized periodontitis
  • Periodontal pocket depth > 3 mm in the related tooth
  • Use of analgesic medication within the past 72 hours
  • Use of antibiotic therapy within the past month
  • Presence of swelling and positive response to palpation/percussion tests

Treatment and study plan

Toluidine Blue O (0.1 mg/mL)

Drug

A 0.1 mg/mL toluidine blue O solution used as the photosensitizer for photodynamic therapy. The solution is placed into the root canal prior to 630-nm LED irradiation for activation.

630-nm LED Light Device

Device

A light-emitting diode device delivering 630-nm wavelength used to activate toluidine blue O during photodynamic therapy. The device is positioned near the tooth for 60 seconds.

Photodynamic Therapy (PDT)

Procedure

Application of 0.1 mg/mL toluidine blue O into the root canal, followed by activation with a 630-nm LED light source for 60 seconds as part of the experimental disinfection protocol.

Sham Photodynamic Therapy

Procedure

Placebo photodynamic procedure in which the LED device is positioned similarly but activated without delivering light energy; no toluidine blue O is applied.

Primary outcomes

  1. Reduction in intracanal bacterial load measured by quantitative PCR (qPCR)

    Time frame: Baseline (Day 1) to Immediately After Intervention (Day 1)

    Intracanal bacterial load will be quantified using real-time quantitative polymerase chain reaction (qPCR). Samples will be collected at four predefined sampling points (S0-S3) using sterile #30 paper points inserted into the canal for 30 seconds.

    S0 (Baseline): After isolation and disinfection, before instrumentation

    S1: After access cavity preparation and working length determination

    S2: After root canal instrumentation

    S3 (Post-Intervention): After final irrigation protocol and photodynamic therapy (or sham procedure)

    Changes in bacterial DNA concentration (copy number/µL) from S0 to S3 will be compared between groups.

Secondary outcomes

  1. Postoperative pain levels measured using the Visual Analog Scale (VAS, 0-100)

    Time frame: 6 hours, 12 hours, 24 hours, Day 3, Day 5, and Day 7 after treatment.

    Postoperative pain intensity will be measured using the Visual Analog Scale (VAS), a 100-mm line ranging from 0 to 100, where 0 represents "no pain" and 100 represents "worst imaginable pain." Higher scores indicate worse pain. Participants will record their pain levels at each scheduled assessment time point.

Sponsors and collaborators

Lead sponsor

Ataturk University

Other

Registry information

Official study title

Evaluation of the Antibacterial Activity and Postoperative Pain Outcomes of Photodynamic Therapy Using Toluidine Blue

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Dec 5, 2025
Registry last updated
Dec 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.